Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.

Blood (2009) 114 (22): 2211.

https://doi.org/10.1182/blood.V114.22.2211.2211

Published: 2009

Journal Articles

FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment.

Daniela Cilloni, MD, PhD, Cristina Panuzzo, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Paolo Nicoli, MD, Emanuela Messa, MD, Stefano Ulisciani, MD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Enrico Bracco, PhD, Thea Kalebic, MD, Giuseppe Saglio, MD

Blood (2007) 110 (11): 1010.

https://doi.org/10.1182/blood.V110.11.1010.1010

Published: 2007

Journal Articles

Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.

Giovanna Rege-Cambrin, PhD, Stefano Ulisciani, MD, Giovanna Mattioli, MD, Carmen Fava, MD, Emilia Giugliano, BD, Vanessa Brunetto, BD, Enrico Gottardi, BD, Milena Fava, BD, Giuseppe Saglio, MD

Blood (2007) 110 (11): 1956.

https://doi.org/10.1182/blood.V110.11.1956.1956

Published: 2007

Journal Articles

Development of a Genetic Tool Based on BCR-ABL Transgenic Drosophila Melanogaster for Identification of Genes Involved in CML Progression and Drug Testing.

Daniela Cilloni, MD, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Enrico Bracco, PhD, Paolo Nicoli, MD, Emanuela Messa, MD, Stefano Ulisciani, MD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Thea Kalebic, MD, Michele Baccarani, MD, Fabian Feiguin, MD, PhD, Giuseppe Saglio, MD

Blood (2007) 110 (11): 468.

https://doi.org/10.1182/blood.V110.11.468.468

Published: 2007

Journal Articles

A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML.

Emilia Giugliano, BD, Dario Ferrero, MD, Carmen Fava, MD, Chiara Dellacasa, MD, Giovanna Mattioli, MD, Patrizia Scaravaglio, BD, Enrico Gottardi, Stefano Ulisciani, MD, Filomena Daraio, BD, Giuseppe Saglio, MD, Giovanna Rege-Cambrin, MD

Blood (2006) 108 (11): 4910.

https://doi.org/10.1182/blood.V108.11.4910.4910

Published: 2006

NARROW

Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.

FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment.

Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.

Development of a Genetic Tool Based on BCR-ABL Transgenic Drosophila Melanogaster for Identification of Genes Involved in CML Progression and Drug Testing.

A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML.

Email alerts

ASH Publications

American Society of Hematology

Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.

FoxO Transcription Factor Is Delocalized in CML Patients by Bcr-Abl Induced PI3K/AKT Activation and IKK Pathway and Can Be Reactivated by Imatinib Treatment.

Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation.

Development of a Genetic Tool Based on BCR-ABL Transgenic Drosophila Melanogaster for Identification of Genes Involved in CML Progression and Drug Testing.

A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only